Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations-Reference-Cited by-同舟云学术

Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations

Published:2021-12 Issue: Volume:159 Page:227-236
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Vassella Erik^ORCID,Kashani Elham^ORCID,Zens Philipp^ORCID,Kündig Alexandra,Fung Christian,Scherz Amina^ORCID,Herrmann Evelyn^ORCID,Ermis Ekin^ORCID,Schmid Ralph A.,Berezowska Sabina^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Epidemiology of brain metastases;Nayak;Curr Oncol Rep,2012

3. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers;Berghoff;ESMO Open,2016

4. Epidemiology of brain metastases and leptomeningeal disease;Lamba;Neuro Oncol,2021

5. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic;Vilarino;Cancer Treat Rev,2020

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis;Lung Cancer;2024-07

2. Genetic profiles of oligometastatic non-small-cell lung cancer and corresponding brain metastases;European Journal of Cardio-Thoracic Surgery;2024-05-25

3. Resistance to KRAS inhibition in advanced non-small cell lung cancer;Frontiers in Oncology;2024-05-23

4. PMS2 amplification contributes brain metastasis from lung cancer;Biological Procedures Online;2024-05-07

5. Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system;Heliyon;2024-05